Interleukin-6-type cytokines in vivo: Regulated bioavailability

Proceedings of the Society for Experimental Biology and Medicine

Volumn 213, Issue 3, 1996, Pages 238-247

  Sehgal, Pravin B ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; NEUTRALIZING ANTIBODY;

BIOAVAILABILITY; CANCER PATIENT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOREACTIVITY; INFLAMMATION; INJURY; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR WEIGHT; REVIEW;

EID: 0030463760     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.3181/00379727-213-44055     Document Type: Review

References (73)

1. Sehgal PB, Tosato G, Grieninger G, Eds. Regulation of the acute phase and immune responses: interleukin-6. Ann NY Acad Sci 557:1-583, 1989.
2. Van Snick J. Interleukin-6: An overview. Annu Rev Immunol 8:253-278, 1990.
3. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood 86:1243-1254, 1995.
4. Mackiewicz A, Koj A, Sehgal PB, Eds. Interleukin-6-type cytokines. Ann NY Acad Sci 762:1-513, 1995.
5. May LT, Neta R, Moldawer LL, Kenney JS, Patel K, Sehgal PB. Antibodies chaperone circulating IL-6: Paradoxical effects of anti-IL-6 "neutralizing" antibodies in vivo. J Immunol 151: 3225-3236, 1993.
6. Finkelman FD, Madden KB, Morris SC, Holmes JM, Boiani N, Katona IM, Maliszeski CR. Anti-cytokine antibodies as carrier proteins: prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J Immunol 151:1235-1244, 1993.
7. Lu ZV, Brochier J, Wijdenes J, Brailly H, Bataille R, Klein B. High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo. Eur J Immunol 22:2819-2824, 1992.
8. May LT, Viguet H, Kenny JS, Ida N, Allison AC, Sehgal PB. High levels of "complexed" IL-6 in human blood. J Biol Chem 267:19698-19704, 1992.
9. May LT, Patel K, Garcia D, Ndubuisi MI, Ferrone S, Mittelman A, Mackiewicz A, Sehgal PB. Sustained high levels of circulating chaperoned interleukin-6 after active specific cancer immunotherapy. Blood 84:1887-1895, 1994.
10. Lahm A, Savino R, Salvati AL, Cabibbo A, Ciapponi L, DeMartis A, Toniatti C, Paonessa G, Altamura S, Ciliberto G. The molecular design of human IL-6 receptor antagonists. Ann NY Acad Sci 762:136-151, 1995.
11. Brakenhoff JPJ, DeHon FD, Aarden LA. Development of human IL-6 receptor antagonists. Ann NY Acad Sci 762:129-135, 1995.
12. Mackiewicz A, Wiznerowicz M, Roeb E, Nowak J, Pawlowski T, Baumann H, Heinrich PC, Rose-John S. Interleukin-6-type Cytokines and their receptors for gene therapy of melanoma. Ann NY Acad Sci 762:361-374, 1995.
13. Economides AN, Ravetch JV, Yancopoulos GD, Stahl N. Designer cytokines: Targeting actions to cells of choice. Science 270:1351-1353, 1995.
14. Gailard J-P, Bataille R, Brailly H, Zuber C, Yasukawa K, Attal M, Maruo N, Taga T, Kishimoto T, Klein B. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur J Immunol 23:820-824, 1993.
15. Narazaki M, Yasukawa K, Saito T, Ohsugi Y, Fukui H, Koishihara Y, Yancopoulos GD, Taga T, Kishimoto T. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 82:1120-1126, 1993.
16. Weissenbach J, Chernajovsky Y, Zeevi M, Shulman L, Soreq M, Nir U, Wallach D, Perricaudet M, Tiollais P, Revel M. Two interferon mRNAs in human fibroblasts: In vitro translation and E. coli cloning studies. Proc Natl Acad Sci USA 77:7152-7156, 1980.
17. Sehgal PB, Sagar AD. Heterogeneity of poly(I)poly(C)-induced human fibroblast interferon mRNA species. Nature 287:95-97, 1980.
18. 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 84:7251-7255, 1987.
19. Ritchie DG, Fuller GM. Hepatocyte stimulating factor: a monocyte-derived acute phase regulatory protein. Ann NY Acad Sci 408:490-502, 1983.
20. Ritchie DG, Levy BA, Adams MA, Fuller GM. Regulation of fibrinogen synthesis by plasmin-derived fragments of fribinogen and fibrin: An indirect feedback pathway. Proc Natl Acad Sci USA 79:175-179, 1982.
21. Hirano T, Taga T, Nakano N, Yasukawa K, Kashiwamura S, Shimizu K, Nakajima K, Pyun KH, Kishimoto T. Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci USA 82:5490-5494, 1985.
22. Hirano T, Taga T, Yasukawa K, Nakajima K, Nakano N, Takatsuki F, Shimizu M, Murashima A, Tsunasawa S, Sakiyama F, Kishimoto T. Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. Proc Natl Acad Sci USA 84:228-231, 1987.
23. Aarden LA, Lansdorp PM, de Groot ER. A growth factor for B-cell hybridomas produced by human monocytes. Lymphokines 10:175-185, 1985.
24. Nordan R, Potter M. A macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro. Science 233:566-569, 1986.
25. Cernetti C, Steinman RM, Piperno-Granelli A. Identification of a 24-kDa cytokine that is required for development of cytolytic T-lymphocytes. Proc Natl Acad Sci USA 85:1605-1609, 1988.
26. Takai Y, Wong GG, Clark SC, Burakoff SJ, Hermann SH. B cell stimulatory factor 2 is involved in the differentiation of cytotoxtic T lymphocytes. J Immunol 140:508-512, 1988.
27. 2 interferon) functions as a second signal for interleukin-2 production by mature murine T cells. Proc Natl Acad Sci USA 84:7629-7633, 1987.
28. Shabo Y, Lotem J, Rubinstein M, Revel M, Clark SC, Wolf SF, Kamen R, Sachs L. The myeloid blood cell differentiation-inducing protein MGI-2A is interleukin-6. Blood 72:2070-2073, 1988.
29. 2/IL-6 augments the activity of human natural killer cells. J Immunol 143:1206-1209, 1989.
30. Grossman RM, Krueger J, Yourish D, Granelli-Piperno A, Murphy DP, May LT, Kupper TS, Sehgal PB, Gottlieb A. Interleukin-6 (IL-6) is expressed in high levels in psoriatic skin and stimulates proliferation of cultured keratinocytes. Proc Natl Acad Sci USA 86:6367-6371, 1989.
31. 2. Proc Natl Acad Sci USA 85:8037-8041, 1989.
32. Tamm I, Cardinale I, Krueger J, Murphy JS, May LT, Sehgal PB. Interleukin-6 decreases cell-cell association and increases motility of ductal breast carcinoma cells. J Exp Med 170:1649-1669, 1989.
33. 1-antitrypsin in human mononuclear phagocytes and in human hepatoma lines. J Clin Invest 84:138-144, 1989.
34. 2 (Interleukin-6) stimulates synthesis of complement proteins factor B and C3 in human skin fibroblasts. Eur J Immunol 19:983-988, 1989.
35. Ikebuchi K, Wong GG, Clark SC, Ihle JN, Hirai Y, Ogawa M. Interleukin-6 enhancement of interleukin-3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci USA 84:9035-9039, 1987.
36. Satoh T, Nakamura S, Taga T, Matsuda T, Hirano T, Kishimoto T, Kaziro Y. Induction of neuronal differentiation in PC12 cells by B-cell stimulatory factor 2/Interleukin-6. Mol Cell Biol 8:3546-3549, 1988.
37. Naitoh Y, Fukuta J, Tominaga T, Nagai Y, Tamai S, Mori K, Imura H. IL-6 stimulates the secretion of adrenocorticotropic hormone in conscious freely-moving rats. Biochem Biophys Res Commun 155:1459-1465, 1988.
38. 2-interferon gene. Proc Natl Acad Sci USA 83:5219-5222, 1986.
39. Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, Kashiwamura S, Nakajima K, Koyama K, Iwamatsu A, , Tsunasawa S, Sakiyama F, Matsui H, Takahara Y, Taniguchi T, Kishimoto T. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324:73-76, 1986.
40. Haegeman C, Content J, Volckaert G, Derynck R, Tavernier J, Fiers W. Structure analysis of the sequence coding for an inducible 26 kDa protein in human fibroblasts. Eur J Biochem 159:625-632, 1986.
41. 2 interferon involved. Proc Natl Acad Sci USA 83:8957-8961, 1986.
42. 2, a distinct species inducible by growth stimulatory cytokines. EMBO J 5:2529-2537, 1986.
43. 2-interferon/B-cell differentiation factor/hepatocyte stimulating factor by human fibroblasts and monocytes. J Biol Chem 262:7760-7766, 1988.
44. May LT, Shaw JE, Khanna AK, Zabriskie JB, Sehgal PB. Marked cell-type-specific differences in glycosylation of human interleukin-6. Cytokine 3:204-211, 1991.
45. May LT, Santhanam U, Tatter SB, Bhardwaj N, Ghrayeb J, Sehgal PB. Phosphorylation of secreted forms of IL-6. Biochem Biophys Res Commun 152:1144-1150, 1988.
46. 2 interferon/hepatocyte stimulating factor/IL-6 promoter by cytokines, viruses and second messenger agonists. Proc Natl Acad Sci USA 85:6701-6705, 1988.
47. Ray A, Sassone-Corsi P, Sehgal PB. A mulliple cytokine- and second-messenger-responsive element in the enhancer of the human interleukin-6 gene: Similarities with c-fos gene regulation. Mol Cell Biol 9:5537-5547, 1989.
48. Ray A, Tatter SB, Santhanam U, Helfgott DC, May LT, Sehgal PB. Regulation of expression of IL-6: Molecular and clinical studies. Ann NY Acad Sci 557:353-362, 1989.
49. Ray A, LaForge KS, Sehgal PB. On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: Enhancer, TATA box, and RNA start site (Inr motif) occlusion. Mol Cell Biol 10:5736-5746, 1990.
50. Santhanam U, Ray A, Sehgal PB. Repression of the interleukin-6 promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci USA 88:7605-7609, 1991.
51. Margulies L, Sehgal PB. Modulation of the human interleukin-6 (IL-6) promoter and transcription factor C/EBPβ (NF-IL6) activity by p53 species. J Biol Chem 268:15096-15100, 1993.
52. Sehgal PB, Margulies L. Cell-type and promoter-dependent ts phenotype of p53 Val-135. Oncogene 8:3417-3419, 1993.
53. Ray A, Prefontaine KE. Physical association and functional antagonism between the p65 subunit of transcription factor NF-κB and the glucocorticoid receptor. Proc Natl Acad Sci USA 91:752-756, 1994.
54. Ray A, Zhang DH, Siegel MD, Ray P. Regulation of interleukin-6 gene expression by steroids. Ann NY Acad Sci 762:79-88, 1995.
55. Ray A, Prefontaine KE, Ray P. Down-modulation of interleukin-6 gene expression by 17β-estradiol in the absence of high affinity DNA binding by the estrogen receptor. J Biol Chem 259:12940-12946, 1994.
56. Stein B, Yang MX. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-κB and C/EBPβ. Mol Cell Biol 15:4971-1979, 1995.
57. Yamasaki K, Taga T, Hirata Y, Yawata H, Kawanishi Y, Seed B, Taniguchi T, Hirano T, Kishimoto T. Cloning and expression of human IL-6 receptor. Science 241:825-828, 1988.
58. Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K, Matsuda T, Hirano T, Kishimoto T. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58:573-581, 1989.
59. Novick D, Engelman H, Wallach D, Rubinstein M. Soluble cytokine receptors are present in normal human urine. J Exp Med 170:1409-1414, 1989.
60. Akira S, Nishio Y, Tanaka T, Inoue M, Matsuka T, Wang XJ, Wei S, Kishimoto T. Transcription factors NF-IL6 and APRF involved in gp130-mediated signaling pathway. Ann NY Acad Sci 762:15-28, 1995.
61. Mackiewicz A, Schooltink H, Heinrich PC, Rose-John S. The complex of soluble human interleukin-6 receptor/interleukin-6 upregulates expression of acute phase proteins. J Immunol 149:2021-2027, 1992.
62. Ihle JN, Witthuhn QFW, Yamamoto K, Thierfelder WE, Krieder B, Silvennoinen O. Signalling by the cytokine receptor superfamily: JAKs and STATs. TIBS 19:222-227, 1994.
63. Nakajima K, Matsuda T, Fujitani Y, Kojima H, Yamanaka Y, Nakae K, Takeda T, Hirano T. Signal transduction through IL-6 receptor: Involvement of multiple protein kinases, stat Factors, and a novel H7-sensitive pathway. Ann NY Acad Sci 762:55-70, 1995.
64. Oldenberg HSA, Rogy MA, Lazarus DD, Van Zee K, Keeler BP, Chizzonite RA, Lowry SF, Moldawer LL. Cachexia and the acute-phase protein response in inflammation are regulated by interleukin-6. Eur J Immunol 23:1889-1894, 1993.
65. Heremans H, Dillen C, Put W, Van Damme J, Billiau A. Protective effect of anti-IL-6 antibody against endotoxin, associated with paradoxically increased IL-6 levels. Eur J Immunol 22:2395-2400, 1992.
66. Klein B, Wijdenes J, Zhang X-G. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 78:1198-1204, 1991.
67. Beck JT, Hsu S-M, Wijdenes J, Bataille R, Klein B, Vesole D, Hayden K, Jagannath S, Barlogie B. Brief report: Alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 330:602-605, 1994.
68. 2/interleukin-6 in plasma and body fluids acute bacterial infection. J Immunol 142:948-953, 1989.
69. Van Oers MHJ, Van Der Heyden AAPAM, Aarden L. Interleukin-6 in serum and urine of renal transplant recipients. Clin Exp Immunol 71:314-320, 1988.
70. Hansen MB, Svenson M, Diamant M, Bendtzen K. Anti-interleukin-6 antibodies in normal human serum. Scand J Immunol 33:777-781, 1991.
71. Hansen MB, Svenson M, Diamant M, Bendtzen K. High affinity IgG autoantibodies to IL-6 in sera of normal individuals are competitive inhibitors of IL-6 in vitro. Cytokine 5:72-80, 1993.
72. DeBenedetti F, Massa M, Pignatti P, Albani S, Novick D, Martini A. Serum soluble interleukin 6 (IL-6) receptor and IL-6/ soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest 93:2114-2119, 1994.
73. Ndubuisi M, Patel K, May LT, Mittelman A, Sehgal PB. Sustained high levels of circulating interleukin-6 in patients subjected to active anti-cancer immunization protocols: Anti-IL-6 and anti-sIL-6R IgG. (abstract) Ann Meeting, Am Assoc Imm, 1996.